Bio-Pharma Market Recent Advancements To Give A Huge Blow To The U.S.

1
United States Bio-Pharma Market Report 2017
2
Report Description
United States Bio-Pharma Market Report 2017
Order This Report by calling BigMarketResearch.com
at 1-971-202-1575.   The pharmaceuticals market
has immensely flourished over the past few years.
This trend has been witnessed mostly in the U.S.
owing to technological advancement and better
infrastructure qualities in comparison to any
other region. A recently added report by Big
Market Research on the pharmaceutical sector,
titled, United States Bio-Pharma Market Report
2017 highlights such factors.   There have been
various attempts by the manufacturers of the U.S.
bio-pharma market to ensure progress of the
industry. Recently, AstraZeneca, an U.S. based
firm has revealed its new data on how they expand
portfolio regarding cancer medicines. They
revealed this information at American Society of
Clinical Oncology (ASCO) in 2017. The company
claims that three new oncology medicines would
help to address the unfulfilled requirements of
patients with bladder cancer, lung, and ovarian.
These have been given permission to be sold in
the market within three years after it put
forward its proposal. The company is at midway to
deliver on its pledge to launch six latest
therapeutic intervention for cancer by 2020.
3
Report Description
Several manufacturers have tried to access the
U.S. biopharma market for many years. Recently,
Celltrion, a South Korean based biopharma company
has planned to ask for approval for two more bio
similar products from Foods and Drugs
Administration (FDA). Request sample report _at_
http//bit.ly/2sdcmZ3 Earlier, the firm has
manufactured bio-similar copy of Remicade which
was originally manufactured by Johnson Johnson
has hit the US market in 2016. Of late, Celltrion
has claimed that it strategies to file Herzuma
and Truxima which are in referenc to lymphatic
cancer drug by Roche in the name of Rituxan
(rituximab) and breast cancer therapy Herceptin
(trastuzumab), respectively. The firm
anticipates that it would get permission by June
2017. Once the company gets approval then its
products which include Truxima and Herzuma would
be sold in the US with the help of Teva
Pharmaceutical Industries, which is the largest
producer of generic drugs in the world.
4
Table of Contents
In this report, the United States Bio-pharma
market is valued at USD XX million in 2016 and is
expected to reach USD XX million by the end of
2022, growing at a CAGR of XX between 2016 and
2022. Geographically, this report splits the
United States market into seven regions The
West Southwest The Middle Atlantic The
Midwest with sales (volume), revenue (value),
market share and growth rate of Bio-pharma in
these regions, from 2012 to 2022
(forecast). United States Bio-pharma market
competition by top manufacturers/players, with
Bio-pharma sales volume, price, revenue (Million
USD) and market share for each manufacturer/player
the top players including Pfizer F. Hoffmann-La
Roche AG Johnson Johnson Services Sanofi, Amgen
5
Table of Contents
1 Bio-pharma Overview1.1 Product Overview and
Scope of Bio-pharma1.2 Classification of
Bio-pharma by Product Category1.2.1 United
States Bio-pharma Market Size (Sales Volume)
Comparison by Type (2012-2022) 2 United States
Bio-pharma Market Competition by
Players/Suppliers2.1 United States Bio-pharma
Sales and Market Share of Key Players/Suppliers
(2012-2017)2.2 United States Bio-pharma Revenue
and Share by Players/Suppliers (2012-2017)2.3
United States Bio-pharma Average Price by
Players/Suppliers (2012-2017) 3 United States
Bio-pharma Sales (Volume) and Revenue (Value) by
Region (2012-2017)3.1 United States Bio-pharma
Sales and Market Share by Region (2012-2017)3.2
United States Bio-pharma Revenue and Market Share
by Region (2012-2017)3.3 United States
Bio-pharma Price by Region (2012-2017) 4 United
States Bio-pharma Sales (Volume) and Revenue
(Value) by Type (Product Category)
(2012-2017)4.1 United States Bio-pharma Sales
and Market Share by Type (Product Category)
(2012-2017)4.2 United States Bio-pharma Revenue
and Market Share by Type (2012-2017)4.3 United
States Bio-pharma Price by Type (2012-2017)4.4
United States Bio-pharma Sales Growth Rate by
Type (2012-2017)
6
Table of Contents
5 United States Bio-pharma Sales (Volume) by
Application (2012-2017) 5.1 United States
Bio-pharma Sales and Market Share by Application
(2012-2017) 5.2 United States Bio-pharma Sales
Growth Rate by Application (2012-2017) 5.3 Market
Drivers and Opportunities 6 United States
Bio-pharma Players/Suppliers Profiles and Sales
Data 6.1 Pfizer 6.1.1 Company Basic Information,
Manufacturing Base and Competitors 6.1.2
Bio-pharma Product Category, Application and
Specification 6.1.3 Pfizer Bio-pharma Sales,
Revenue, Price and Gross Margin (2012-2017) 6.1.4
Main Business/Business Overview 6.2 F.
Hoffmann-La Roche AG6.2.2 Bio-pharma Product
Category, Application and Specification6.2.3 F.
Hoffmann-La Roche AG Bio-pharma Sales, Revenue,
Price and Gross Margin (2012-2017)6.2.4 Main
Business/Business Overview
7
Visit us at
https//www.bigmarketresearch.com/United-States-Bi
o-pharma-Report-2017-market
Stay With Us
TELEPHONE [phone] EMAIL
help_at_bigmarketresearch.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States